Pompe Disease News and Research

RSS
Pompe disease is a rare and often fatal muscle disease caused by an inherited deficiency of the enzyme acid alpha-glucosidase, which is responsible for breaking down glycogen within cells. Pompe disease ranges from a rapidly fatal infantile-onset form with severe cardiac involvement to a more slowly progressive late-onset form primarily affecting skeletal muscle. There is currently no therapeutic treatment available for the disease, which affects an estimated 5,000-10,000 people worldwide.
Adeno-associated virus: The gene therapy revolution faces manufacturing and safety hurdles

Adeno-associated virus: The gene therapy revolution faces manufacturing and safety hurdles

Pioneering AI-based approach identifies rare disease patients using electronic health records

Pioneering AI-based approach identifies rare disease patients using electronic health records

Duke scientists join team involved in the first use of fetal therapy for Pompe disease

Duke scientists join team involved in the first use of fetal therapy for Pompe disease

FDA approves an intravenous medication to treat patients with Pompe disease

FDA approves an intravenous medication to treat patients with Pompe disease

New and more effective treatment for Pompe disease

New and more effective treatment for Pompe disease

Spark Therapeutics launches gene therapy clinical trial for late-onset Pompe disease

Spark Therapeutics launches gene therapy clinical trial for late-onset Pompe disease

Researchers use guide RNAs to improve base editing system

Researchers use guide RNAs to improve base editing system

New, sensitive screening test may allow clinicians to accurately detect Pompe disease

New, sensitive screening test may allow clinicians to accurately detect Pompe disease

Counteracting premature aging

Counteracting premature aging

New gene therapy for Pompe disease may replace currently available treatments

New gene therapy for Pompe disease may replace currently available treatments

Combined genetic disruptions can counteract premature aging, TSRI study suggests

Combined genetic disruptions can counteract premature aging, TSRI study suggests

Researchers find conceivable alternative way to treat Pompe disease

Researchers find conceivable alternative way to treat Pompe disease

Researchers develop molecule that binds to GAA enzymes key to progress of Pompe disease

Researchers develop molecule that binds to GAA enzymes key to progress of Pompe disease

New fluorescent chemical probes that measure enzyme levels can diagnose inherited genetic disorders

New fluorescent chemical probes that measure enzyme levels can diagnose inherited genetic disorders

Valerion announces positive results from non-clinical pilot study of VAL-1221 for treatment of Pompe disease

Valerion announces positive results from non-clinical pilot study of VAL-1221 for treatment of Pompe disease

Synageva announces submission of Kanuma application to Cofepris for treatment of LAL Deficiency

Synageva announces submission of Kanuma application to Cofepris for treatment of LAL Deficiency

European scientists set up new therapeutic approaches to tackle gene defects

European scientists set up new therapeutic approaches to tackle gene defects

Research suggests that person can slow aging process by exercising regularly

Research suggests that person can slow aging process by exercising regularly

Longer looks: Doctor guilt; an abortion provider's hidden record

Longer looks: Doctor guilt; an abortion provider's hidden record

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.